SEC Form 4 · accession 0001877589-26-000002
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eli Samaha
10% Owner
Period of report
Jul 6, 2026
Accepted (ET)
Jul 8, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMF1 | Jul 6, 2026 | S | 1,400 | $17.04 | D | 9,173,053 | I | See Footnotes |
| COMF2,F1 | Jul 7, 2026 | S | 5,564 | $17.1712 | D | 9,167,489 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.
- F2The sales price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.